1-9 of 9
Catherine Williams
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Ola Landgren, MD PhD, Michele Cavo, MD, Ajai Chari, MD, Yael C Cohen, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter M. Voorhees, MD, Jane Estell, FRACP, Irwindeep Sandhu, MDFRCPC, Matthew Jenner, Catherine Williams, Niels WCJ van de Donk, MD PhD, Meral Beksac, MD, Hartmut Goldschmidt, MD, Philippe Moreau, Steven Kuppens, Rajesh Bandekar, Tobias Neff, Annelore Cortoos, MD, Pamela L Clemens, PhD, Ming Qi, Homer Adams, III, PhD, Craig C Hofmeister, MDMPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 1994.
https://doi.org/10.1182/blood-2018-99-113467
Published: 2018
Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen
Journal: Blood
Blood (2018) 132 (Supplement 1): 802.
https://doi.org/10.1182/blood-2018-99-116426
Published: 2018
Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen
Journal: Blood
Blood (2018) 132 (Supplement 1): 306.
https://doi.org/10.1182/blood-2018-99-116624
Published: 2018
Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Graham H Jackson, Faith E. Davies, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, Alina Striha, Anna Hockaday, Corinne Collett, John R Jones, Bhuvan Kishore, Mamta Garg, Catherine Williams, Kamaraj Karunanithi, Jindriska Lindsay, Matthew Jenner, Gordon Cook, Nigel H. Russell, Martin Kaiser, MD, Mark T Drayson, Roger G. Owen, Walter M Gregory, Gareth Morgan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 302.
https://doi.org/10.1182/blood-2018-99-114956
Published: 2018
Journal Articles

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Graham H Jackson, David Cairns, Alina Striha, Anna Hockaday, Gwen Jacques, John R Jones, Kevin Boyd, Bhuvan Kishore, Mamta Garg, Catherine Williams, Kamaraj Karunanithi, Jindriska Lindsay, Matthew Jenner, Gordon Cook, Nigel H. Russell, Martin Kaiser, MD, Mark T Drayson, Roger G. Owen, Walter M Gregory, Gareth Morgan, MD, Faith E. Davies, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3280.
https://doi.org/10.1182/blood-2018-99-118868
Published: 2018
Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Kwee L Yong, MBChB, PhD, Sarah Brown, Samantha Hinsley, Louise Flanagan, Neil Rabin, MB,BS, PhD, Karthik Ramasamy, Jamie Cavenagh, Roger G Owen, Martin F Kaiser, MD, Eric Low, Catherine Williams
Journal: Blood
Blood (2015) 126 (23): 1840.
https://doi.org/10.1182/blood.V126.23.1840.1840
Published: 2015
Journal Articles

Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, DipRCPath, Simon Hallam, MRCP, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath
Journal: Blood
Blood (2007) 110 (11): 2713.
https://doi.org/10.1182/blood.V110.11.2713.2713
Published: 2007
Journal Articles

A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, BSc, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath
Journal: Blood
Blood (2006) 108 (11): 3542.
https://doi.org/10.1182/blood.V108.11.3542.3542
Published: 2006
Journal Articles

A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Heather E. Oakervee, MRCPath, Nicola Foot, BSc, Samir Agrawal, PhD, Patricia Smith, RGN, Charles Craddock, FRCPath, Catherine Williams, FRCPath, Supratik Basu, FRCPath, Jamie D. Cavenagh, MD
Journal: Blood
Blood (2005) 106 (11): 2555.
https://doi.org/10.1182/blood.V106.11.2555.2555
Published: 2005